Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has been given an average rating of “Buy” by the seven analysts that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $8.50.
DRNA has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Finally, ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 2nd.
In related news, Director Bain Capital Life Sciences Inv acquired 285,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was bought at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 29.41% of the company’s stock.
Several large investors have recently bought and sold shares of DRNA. Northern Trust Corp raised its holdings in shares of Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares in the last quarter. Birchview Capital LP grew its position in shares of Dicerna Pharmaceuticals by 125.0% in the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 25,000 shares during the last quarter. Deschutes Portfolio Strategy LLC purchased a new position in shares of Dicerna Pharmaceuticals in the 3rd quarter worth approximately $575,000. Vanguard Group Inc. grew its position in shares of Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after buying an additional 14,517 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Dicerna Pharmaceuticals by 2.4% in the 1st quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock worth $1,423,000 after buying an additional 9,818 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.
Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) traded up $0.65 during trading hours on Monday, hitting $8.63. 492,548 shares of the company’s stock were exchanged, compared to its average volume of 182,047. Dicerna Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $10.24.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The business had revenue of $0.47 million during the quarter. During the same period in the prior year, the firm earned ($0.68) earnings per share. The firm’s quarterly revenue was up 192.6% on a year-over-year basis. sell-side analysts anticipate that Dicerna Pharmaceuticals will post -3.04 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Dicerna Pharmaceuticals Inc (DRNA) Receives $8.50 Consensus Target Price from Brokerages” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/dicerna-pharmaceuticals-inc-drna-receives-8-50-consensus-target-price-from-brokerages.html.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.